ArticleDermatology reports2025
Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history.
Article in Dermatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis and sarcoidosis are two systemic inflammatory diseases characterized by elevated Th1 and Th17 lymphocyte activity and overlapping genetic components. Although psoriasis often accompanies known comorbidities, the simultaneous presence of acute sarcoidosis (Löfgren syndrome [LöS]) is uncommon. A 23-year-old Caucasian male patient with a history of mild psoriasis without relapse since childhood presented with generalized psoriatic plaques. In May 2020, he experienced symptoms compatible with LöS, which was followed by complete resolution after three months of systemic corticosteroid therapy. After one year of treatment with adalimumab, the Psoriasis Area and Severity Index (PASI) decreased from 25.3 to 4.2, while sarcoidosis remained stable. The common pathogenic mechanisms between psoriasis and sarcoidosis warrant further investigation. This case emphasizes the importance of vigilance for respiratory symptoms in psoriasis patients and the potential for psoriasis recurrence after sarcoidosis. Dermatologists need to be aware of these associations, promoting comprehensive management strategies for psoriatic patients with a history of sarcoidosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.